Codexis (CDXS) Scheduled to Post Earnings on Thursday

Codexis (NASDAQ:CDXS - Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Codexis has set its FY 2024 guidance at EPS.Parties interested in participating in the company's conference call can do so using this link.

Codexis (NASDAQ:CDXS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.18. The company had revenue of $26.56 million for the quarter, compared to analyst estimates of $24.73 million. Codexis had a negative net margin of 108.69% and a negative return on equity of 47.58%. On average, analysts expect Codexis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Codexis Price Performance

Shares of NASDAQ:CDXS traded down $0.15 during mid-day trading on Thursday, reaching $2.65. 281,863 shares of the company's stock were exchanged, compared to its average volume of 554,682. Codexis has a twelve month low of $1.45 and a twelve month high of $4.91. The business's fifty day moving average price is $3.32 and its 200-day moving average price is $2.72.

Wall Street Analysts Forecast Growth

CDXS has been the subject of several research analyst reports. Benchmark raised shares of Codexis from a "hold" rating to a "buy" rating and set a $9.00 price target for the company in a research note on Thursday, February 29th. StockNews.com raised shares of Codexis to a "sell" rating in a research note on Tuesday, March 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $6.80.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.